A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a single arm, multi-center Phase II Study. This clinical study is an
investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the
efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1
antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital